IL137308A - Conductivity-normalized urinary analyte concentration measurement for use in disease diagnosis - Google Patents

Conductivity-normalized urinary analyte concentration measurement for use in disease diagnosis

Info

Publication number: IL137308A
Authority: IL; Israel
Prior art keywords: thromboxane; conductivity; concentration; electrical conductivity; medical condition
Prior art date: 2000-07-13

Application number

IL13730800A

Other languages

English (en)

Other versions

IL137308A0 (en

Inventor

Yoram Rubin

Shai Nimri

Nitsa Galili-Nachshon

Sari Ben-Yaakov

Inbal Ben-Zvi Tzhori

Original Assignee

Analyte Works Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-13

Filing date

2000-07-13

Publication date

2005-12-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11074393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL137308(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-07-13 Application filed by Analyte Works Ltd filed Critical Analyte Works Ltd

2000-07-13 Priority to IL13730800A priority Critical patent/IL137308A/en

2001-07-12 Priority to PCT/IL2001/000642 priority patent/WO2002006830A1/en

2001-07-12 Priority to ES01949857T priority patent/ES2217165T3/es

2001-07-12 Priority to CA002416065A priority patent/CA2416065A1/en

2001-07-12 Priority to EP01949857A priority patent/EP1299719B1/de

2001-07-12 Priority to AT01949857T priority patent/ATE261120T1/de

2001-07-12 Priority to AU2001270968A priority patent/AU2001270968A1/en

2001-07-12 Priority to DE60102245T priority patent/DE60102245T2/de

2001-07-12 Priority to JP2002512688A priority patent/JP2004504605A/ja

2001-07-24 Publication of IL137308A0 publication Critical patent/IL137308A0/xx

2003-01-13 Priority to US10/341,526 priority patent/US20030171698A1/en

2005-12-18 Publication of IL137308A publication Critical patent/IL137308A/en

Links

239000012491 analyte Substances 0.000 title claims abstract description 17
238000003745 diagnosis Methods 0.000 title claims abstract description 16
230000002485 urinary effect Effects 0.000 title claims abstract description 16
238000005259 measurement Methods 0.000 title description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 9
201000010099 disease Diseases 0.000 title description 8
238000000034 method Methods 0.000 claims abstract description 32
210000002700 urine Anatomy 0.000 claims abstract description 23
230000000747 cardiac effect Effects 0.000 claims abstract description 11
230000001154 acute effect Effects 0.000 claims abstract description 9
150000003595 thromboxanes Chemical class 0.000 claims abstract description 4
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 claims description 24
XNRNNGPBEPRNAR-JQBLCGNGSA-N thromboxane B2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1OC(O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O XNRNNGPBEPRNAR-JQBLCGNGSA-N 0.000 claims description 15
XNRNNGPBEPRNAR-UHFFFAOYSA-N Thromboxane B2 Natural products CCCCCC(O)C=CC1OC(O)CC(O)C1CC=CCCCC(O)=O XNRNNGPBEPRNAR-UHFFFAOYSA-N 0.000 claims description 14
238000003556 assay Methods 0.000 claims description 10
239000004065 semiconductor Substances 0.000 claims description 5
238000003018 immunoassay Methods 0.000 claims description 4
KJYIVXDPWBUJBQ-SLQLHLDPSA-N (z)-7-[(2r,3s,4s)-4-hydroxy-2-[(e,3r)-3-hydroxyoct-1-enyl]-6-oxooxan-3-yl]hept-5-enoic acid Chemical compound CCCCC[C@@H](O)\C=C\[C@H]1OC(=O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O KJYIVXDPWBUJBQ-SLQLHLDPSA-N 0.000 claims description 3
KJYIVXDPWBUJBQ-UHFFFAOYSA-N 11-Dehydro-Thromboxane B2 Natural products CCCCCC(O)C=CC1OC(=O)CC(O)C1CC=CCCCC(O)=O KJYIVXDPWBUJBQ-UHFFFAOYSA-N 0.000 claims description 3
239000000203 mixture Substances 0.000 claims description 2
238000004458 analytical method Methods 0.000 description 8
239000003814 drug Substances 0.000 description 6
230000035945 sensitivity Effects 0.000 description 6
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
229940079593 drug Drugs 0.000 description 5
206010008479 Chest Pain Diseases 0.000 description 4
230000008901 benefit Effects 0.000 description 4
238000011161 development Methods 0.000 description 4
208000019622 heart disease Diseases 0.000 description 4
208000004476 Acute Coronary Syndrome Diseases 0.000 description 3
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
208000020446 Cardiac disease Diseases 0.000 description 3
208000024172 Cardiovascular disease Diseases 0.000 description 3
229960001138 acetylsalicylic acid Drugs 0.000 description 3
238000007405 data analysis Methods 0.000 description 3
230000002526 effect on cardiovascular system Effects 0.000 description 3
230000036541 health Effects 0.000 description 3
238000010606 normalization Methods 0.000 description 3
DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 3
238000002965 ELISA Methods 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
238000011088 calibration curve Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
230000007170 pathology Effects 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
206010002388 Angina unstable Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000283074 Equus asinus Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
208000007814 Unstable Angina Diseases 0.000 description 1
206010000891 acute myocardial infarction Diseases 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000004931 aggregating effect Effects 0.000 description 1
230000000479 anti-thromboxane effect Effects 0.000 description 1
239000012131 assay buffer Substances 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
238000003759 clinical diagnosis Methods 0.000 description 1
230000008602 contraction Effects 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000008151 electrolyte solution Substances 0.000 description 1
208000035474 group of disease Diseases 0.000 description 1
238000011534 incubation Methods 0.000 description 1
201000004332 intermediate coronary syndrome Diseases 0.000 description 1
238000011835 investigation Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
239000004575 stone Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
239000001117 sulphuric acid Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
150000003593 thromboxane B2 derivatives Chemical class 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000002562 urinalysis Methods 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Hematology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Investigating Or Analysing Biological Materials (AREA)
Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)

IL13730800A 2000-07-13 2000-07-13 Conductivity-normalized urinary analyte concentration measurement for use in disease diagnosis IL137308A (en)

Priority Applications (10)

Application Number	Priority Date	Filing Date	Title
IL13730800A IL137308A (en)	2000-07-13	2000-07-13	Conductivity-normalized urinary analyte concentration measurement for use in disease diagnosis
JP2002512688A JP2004504605A (ja)	2000-07-13	2001-07-12	電気伝導度で標準化した尿中分析対象物濃度測定値の疾病診断における使用
EP01949857A EP1299719B1 (de)	2000-07-13	2001-07-12	Anhand der konduktivität normalisierte bestimmung von analyten in urin zur diagnose von krankheiten
ES01949857T ES2217165T3 (es)	2000-07-13	2001-07-12	Medida de la concentracion de una analito urinario despues de normalizar la conductividad, para diagnostico de enfermedades.
CA002416065A CA2416065A1 (en)	2000-07-13	2001-07-12	Conductivity-normalized urinary analyte concentration measurement for use in disease diagnosis
PCT/IL2001/000642 WO2002006830A1 (en)	2000-07-13	2001-07-12	Conductivity-normalized urinary analyte concentration measurement for use in disease diagnosis
AT01949857T ATE261120T1 (de)	2000-07-13	2001-07-12	Anhand der konduktivität normalisierte bestimmung von analyten in urin zur diagnose von krankheiten
AU2001270968A AU2001270968A1 (en)	2000-07-13	2001-07-12	Conductivity-normalized urinary analyte concentration measurement for use in disease diagnosis
DE60102245T DE60102245T2 (de)	2000-07-13	2001-07-12	Anhand der konduktivität normalisierte bestimmung von analyten in urin zur diagnose von krankheiten
US10/341,526 US20030171698A1 (en)	2000-07-13	2003-01-13	Conductivity-normalized urinary analyte concentration measurement for use in disease diagnosis

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IL13730800A IL137308A (en)	2000-07-13	2000-07-13	Conductivity-normalized urinary analyte concentration measurement for use in disease diagnosis

Publications (2)

Publication Number	Publication Date
IL137308A0 IL137308A0 (en)	2001-07-24
IL137308A true IL137308A (en)	2005-12-18

Family

ID=11074393

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL13730800A IL137308A (en)	2000-07-13	2000-07-13	Conductivity-normalized urinary analyte concentration measurement for use in disease diagnosis

Country Status (10)

Country	Link
US (1)	US20030171698A1 (de)
EP (1)	EP1299719B1 (de)
JP (1)	JP2004504605A (de)
AT (1)	ATE261120T1 (de)
AU (1)	AU2001270968A1 (de)
CA (1)	CA2416065A1 (de)
DE (1)	DE60102245T2 (de)
ES (1)	ES2217165T3 (de)
IL (1)	IL137308A (de)
WO (1)	WO2002006830A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1843850T3 (en)	2005-01-31	2015-12-07	Realbio Technologies Ltd	LATERAL FLOW STEERING CAPILLAR DEVICE
EP1859267A2 (de) *	2005-02-15	2007-11-28	Analyte Works Ltd.	Testvorrichtung zur untersuchung von flüssigkeitsproben, vor allem urin
EP2326419B1 (de)	2008-06-29	2021-04-07	Realbio Technologies Ltd.	Flüssigkeitstransfervorrichtung, die besonders gut als einfangvorrichtung in einem biologischen assayverfahren geeignet ist
WO2013095729A1 (en)	2011-12-22	2013-06-27	Life Technologies Corporation	Sequential lateral flow capillary device for analyte determination

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1254616A (en) *	1985-11-11	1989-05-23	Calum J. Mcneil	Electrochemical enzymic assay procedures
US4963815A (en) *	1987-07-10	1990-10-16	Molecular Devices Corporation	Photoresponsive electrode for determination of redox potential
US5047354A (en) *	1987-10-30	1991-09-10	Foegh Marie L	Thromboxane B2 assay for coronary artery thrombosis
US5439569A (en) *	1993-02-12	1995-08-08	Sematech, Inc.	Concentration measurement and control of hydrogen peroxide and acid/base component in a semiconductor bath
US5955370A (en) *	1993-11-02	1999-09-21	U.D. Testing, Inc.	Urine adulteration test method
JPH10267925A (ja) *	1997-01-27	1998-10-09	Aisin Seiki Co Ltd	検尿方法および検尿装置付きトイレ装置
US5958786A (en) *	1997-08-05	1999-09-28	Bayer Corporation	Fluorescent polymeric sensor for the detection of creatinine
US6241863B1 (en) *	1998-04-27	2001-06-05	Harold G. Monbouquette	Amperometric biosensors based on redox enzymes
US6194224B1 (en) *	1998-07-27	2001-02-27	Avitar, Inc.	Diagnostic membrane containing fatty acid sarcosinate surfactant for testing oral fluid
JP2000131316A (ja) *	1998-10-22	2000-05-12	Toto Ltd	健康管理装置および健康管理システム
US6994983B2 (en) *	1999-10-25	2006-02-07	Esoterix, Inc. Coagulation	Kits for determination of thromboxane B2 metabolite and optimizing aspirin dosage
IL137307A0 (en) *	2000-07-13	2001-07-24	Biopreventive Ltd	A rapid non-invasive method for differential acute cardiac disease diagnosis

2000
- 2000-07-13 IL IL13730800A patent/IL137308A/en not_active IP Right Cessation
2001
- 2001-07-12 AU AU2001270968A patent/AU2001270968A1/en not_active Abandoned
- 2001-07-12 ES ES01949857T patent/ES2217165T3/es not_active Expired - Lifetime
- 2001-07-12 AT AT01949857T patent/ATE261120T1/de not_active IP Right Cessation
- 2001-07-12 DE DE60102245T patent/DE60102245T2/de not_active Expired - Fee Related
- 2001-07-12 EP EP01949857A patent/EP1299719B1/de not_active Expired - Lifetime
- 2001-07-12 WO PCT/IL2001/000642 patent/WO2002006830A1/en not_active Ceased
- 2001-07-12 JP JP2002512688A patent/JP2004504605A/ja active Pending
- 2001-07-12 CA CA002416065A patent/CA2416065A1/en not_active Abandoned
2003
- 2003-01-13 US US10/341,526 patent/US20030171698A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ES2217165T3 (es)	2004-11-01
EP1299719B1 (de)	2004-03-03
DE60102245D1 (de)	2004-04-08
JP2004504605A (ja)	2004-02-12
CA2416065A1 (en)	2002-01-24
EP1299719A1 (de)	2003-04-09
AU2001270968A1 (en)	2002-01-30
IL137308A0 (en)	2001-07-24
US20030171698A1 (en)	2003-09-11
DE60102245T2 (de)	2005-06-30
WO2002006830A1 (en)	2002-01-24
ATE261120T1 (de)	2004-03-15

Legal Events

Date	Code	Title
2006-07-05	FF	Patent granted
2006-09-05	KB	Patent renewed
2011-02-28	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
Clerico et al.	2009	High-sensitivity troponin: a new tool for pathophysiological investigation and clinical practice
US20040015101A1 (en)	2004-01-22	Rapid non-invasive method for differential acute cardiovascular disease diagnosis
Vaidya	1992	Myoglobin
Kavsak et al.	2018	The potential role of a turbidimetric heart-type fatty acid-binding protein assay to aid in the interpretation of persistently elevated, non-changing, cardiac troponin I concentrations
Penttilä et al.	2002	Myoglobin, creatine kinase MB isoforms and creatine kinase MB mass in early diagnosis of myocardial infarction in patients with acute chest pain
Collinson et al.	1995	Rapid troponin T measurement in whole blood for detection of myocardial damage
Lim et al.	2022	Prospective cohort study on the use of low molecular weight heparin calibrated anti-Xa assay for measurement of direct oral Xa inhibitors in ex vivo patient samples
EP1299719B1 (de)	2004-03-03	Anhand der konduktivität normalisierte bestimmung von analyten in urin zur diagnose von krankheiten
WO2020005947A9 (en)	2020-03-05	Methods and kits for detection of 11-dehydro-thromboxane b2
Lapić et al.	2025	Interfering heterophile antibodies as the cause of persistently falsely elevated high-sensitivity troponin I on Alinity i: a case report
Li et al.	2019	Data mining: Biological and temporal factors associated with blood cardiac troponin I concentration in a Chinese population
Kido et al.	2026	Evaluation of salivary calprotectin as a marker for screening periodontitis using a latex agglutination turbidimetric immunoassay system: a cross-sectional study
Noraddin et al.	2012	Measurement of Urinary Cystatin C with a Particle‐Enhanced Turbidimetric Immunoassay on Architect C i8200
Carraro et al.	1994	A new immunoassay for the measurement of myoglobin in serum
Urdal et al.	1982	Age-related reference intervals for creatine kinase BB in serum
Katz et al.	1998	Biochemical markers of acute myocardial infarction: strategies for improving their clinical usefulness
Yang et al.	2020	Performance verification of a new domestic chemiluminescence detection system
Cabrini et al.	1990	An evaluation of an enzyme immunoassay method for immunoreactive trypsin in dried blood spots
Borque et al.	1991	Quantitative automated latex nephelometric immunoassay for determination of myoglobin in human serum
Hedberg et al.	2004	Highly sensitive determination of C-reactive protein on the Innotrac Aio! immunoanalyzer
Cai et al.	2021	Relation of red cell distribution width with HAS-BLED score in patients with non-valvular atrial fibrillation
Apple	1992	Creatine kinase-MB
Brnjarchevska Blazhevska et al.	2020	Comparison of elisa and chemiluminescence immunoassay methods for quantification of human placental growth factor in serum
Lewis Jr et al.	2001	Clinical significance of low-positive troponin I by AxSYM and ACS: 180
Poole et al.	2007	An evaluation of the association between systemic inflammation–as measured by C-reactive protein–and hospital resource use